HHS hands BioCryst $55M for Phase III trial
HHS has awarded BioCryst Pharmaceuticals a $55 million contract modification to fund to completion the Phase II development of peramivir for the treatment of patients hospitalized with influenza. Release
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Latest Commentary
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What's your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- Chronic Pain Is Relieved by Cell Transplantation in Lab Study
- Drug-vaccine combo better for breast cancer
- Marked for destruction: Newly developed compound triggers cancer cell death
- Orthofix International Completes Divestiture of Sports Medicine Business Unit
- ConforMIS iTotal CR Knee Replacement System Wins Silver in 2012 Medical Design Excellence Awards
- More Press Releases
Featured Jobs
-
Senior Engineer, Project Job
Celgene Corporation - Phoenix, AZ, US -
Oncology Knowledge Lead
Merck - Boston, MA -
Director, Quality
Sucampo Pharmaceuticals - Washington, DC -
Statistician Job
Yoh - Montville, NJ, USA -
Senior Scientist - Permanent Job
Yoh - Doylestown, PA, USA
Comments